News Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Market Closed - Canadian Securities Exchange Other stock markets 02:27:53 2024-04-29 pm EDT			5-day change	1st Jan Change
0.175 ^CAD	-20.45%		-2.78%	+20.69%

Apr. 03	Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	CI
Apr. 03	Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Awakn Life Sciences Announces Closing of Tranche of Private Placement	Apr. 17	NE
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic	Apr. 03	NE
Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	Apr. 03	CI
Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	Apr. 02	CI
Canadian Securities Exchange Reports February 2024 Performance Figures	Mar. 15	NE
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)	Feb. 12	NE
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange	Feb. 12	NE
Awakn Life Sciences Announces Conditional Approval of CSE Listing	Feb. 05	NE
Awakn Life Sciences Corp. Designates Program AWKN-002 for Alcohol Use Disorder in the US Market	Jan. 24	CI
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers	Jan. 24	NE
Awakn Life Sciences Corp. Enters Global Licensing Agreement with LTS Lohmann Therapie-Systeme AG	Dec. 20	CI
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS	Dec. 20	NE
Awakn Life Sciences Provides Corporate Update	Dec. 15	NE
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 14	CI
Awakn Life Sciences Corp. Receives Clinical Trial Authorization from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority in the UK for a Phase III Clinical Trial for its Lead Program AWKN-P001 for the Treatment of Severe Alcohol Use Disorder	Nov. 15	CI
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001	Nov. 15	NE
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements	Nov. 10	NE
Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder	23-10-31	NE
Awakn Life Sciences : AWKN Testing	23-10-19	PU
Awakn Life Sciences : AWKN.NE)	23-10-16	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Summary

Filters